To date, the greatest focus has been on the degree of expression of PD-L1 on tumor and infiltrating immune cells, tumor infiltrating lymphocytes (TILs), tumor mutational burden (TMB), neoantigen load [4, 5], and T cell receptor (TCR) clonality (reviewed in [1, 3, 6]). This evidence concerns the gene CD274 and neoplasm.